
Soligenix SNGX
$ 1.16
0.43%
Annual report 2025
added 03-31-2026
Soligenix Interest Expense 2011-2026 | SNGX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Soligenix
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.7 K | 550 K | 43.2 K | 5.92 K | 30.8 K | 61.1 K | 149 K | - | - | 2.22 K | -8.02 K | 1.31 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 550 K | -11.7 K | 82.4 K |
Quarterly Interest Expense Soligenix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.82 K | -7.92 K | -788 | - | 67 K | 64.2 K | 173 K | - | - | 2.35 K | 40.9 K | - | - | - | -146 K | - | 30.8 K | -215 K | -129 K | - | 486 | 2.02 K | 21.9 K | - | - | - | - | - | - | - | - | - | -789 | 5.23 K | 4.75 K | - | 391 K | 1.26 K | -3.88 K | - | -3.73 K | 551 | 561 | - | 428 | 322 | 291 | - | 652 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 391 K | -215 K | 10.6 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
2.28 K | $ 3.85 | 3.22 % | $ 9.26 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
5.2 M | $ 327.0 | -1.92 % | $ 42.8 B | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Cabaletta Bio
CABA
|
2 M | $ 3.52 | 3.38 % | $ 354 M | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
Aligos Therapeutics
ALGS
|
2.2 M | $ 8.24 | 11.12 % | $ 81.5 M | ||
|
Allakos
ALLK
|
8 K | - | - | $ 28.6 M | ||
|
Applied Therapeutics
APLT
|
-27 K | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-93 K | - | -2.5 % | $ 5.88 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 21.94 | 1.2 % | $ 1.03 B | ||
|
CymaBay Therapeutics
CBAY
|
18.9 M | - | - | $ 3.45 B | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 100.85 | 1.39 % | $ 27.2 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
227 K | $ 3.13 | -3.52 % | $ 5.15 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
ContraFect Corporation
CFRX
|
-4.81 M | - | -5.16 % | $ 5.39 M | ||
|
Galectin Therapeutics
GALT
|
1.03 M | $ 2.34 | -8.79 % | $ 150 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
58 K | $ 1.4 | -10.0 % | $ 360 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
6.55 M | $ 4.22 | -0.59 % | $ 451 M | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 24.2 | -1.55 % | $ 3.08 B | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
36.7 M | $ 1.53 | 2.68 % | $ 407 M | ||
|
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B | ||
|
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-257 K | - | -16.75 % | $ 25.8 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 33.66 | -0.62 % | $ 2.24 B | ||
|
bluebird bio
BLUE
|
16.4 M | - | - | $ 546 M |